TAT(SZ:002433)2021-04-28 16:00Financial Performance - The company's revenue for Q1 2021 was ¥775,917,621.13, representing a 3.80% increase compared to ¥747,543,087.58 in the same period last year[8]. - The net profit attributable to shareholders was a loss of ¥59,185,352.61, a significant decline of 478.19% from a profit of ¥15,649,626.85 in the previous year[8]. - The total profit for the reporting period decreased by 86,997,654.74 yuan, a decline of 430.96%, primarily due to increased operating expenses and a decrease in sales of e-commerce purchased products, self-made products, and health industry products[18]. - The net profit for the reporting period decreased by 84,196,633.37 yuan, a decline of 468.33%, attributed to increased operating expenses and decreased sales in key product categories[18]. - The net profit attributable to the parent company's shareholders decreased by 74,834,979.46 yuan, a decline of 478.19%, mainly due to increased operating expenses and reduced sales[19]. - The comprehensive income attributable to the parent company's shareholders decreased by 75,533,813.27 yuan, a decline of 449.59%, driven by increased operating expenses and decreased sales[20]. - The basic earnings per share decreased by 0.10 yuan, a decline of 500%, reflecting the drop in net profit[21]. - Net profit for Q1 2021 was a loss of CNY 66,218,712.44, compared to a profit of CNY 17,977,920.93 in Q1 2020[48]. - The total comprehensive income for the first quarter was -3,868,267.52 CNY, compared to 25,440,626.77 CNY in the previous year[53]. Cash Flow - The net cash flow from operating activities was ¥212,283,756.72, a recovery from a negative cash flow of ¥187,228,455.64 in the same period last year[8]. - The net cash flow from operating activities increased by 399,512,212.36 yuan, a growth of 213.38%, due to reduced purchases of medicines and Chinese herbal materials[22]. - The cash flow from investing activities decreased by 27,976,700 yuan, a decline of 69.94%, primarily due to fewer investment gains from the transfer of subsidiary equity[23]. - The cash and cash equivalents at the end of the reporting period decreased by 206,641,632.67 yuan, a decline of 76.93%, mainly due to the repayment of bank loans[25]. - The cash inflow from investment activities was 12,023,300.00 CNY, compared to 40,000,000.00 CNY in the previous year[57]. - The cash outflow from financing activities was 554,408,267.27 CNY, compared to 334,329,188.04 CNY in the same period last year[57]. - The net cash flow from investing activities was 11,033,000.00, a decrease from 38,308,575.00 in the previous year[60]. - The net cash flow from financing activities was -24,378,916.87, a significant decline from 42,830,249.29 in the previous year[60]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,877,327,761.62, down 2.20% from ¥9,077,058,813.52 at the end of the previous year[8]. - The company's current assets totaled CNY 4,502,691,476.88, down from CNY 4,669,460,347.34, indicating a decrease of about 3.6%[38]. - Total liabilities decreased to CNY 3,522,049,267.82 from CNY 3,656,023,097.44, representing a decline of approximately 3.7%[40]. - The company's equity attributable to shareholders was CNY 5,179,108,003.44, down from CNY 5,237,831,865.89, indicating a decrease of about 1.1%[41]. - The short-term borrowings decreased to CNY 1,338,285,331.32 from CNY 1,581,033,333.36, a reduction of approximately 15.4%[39]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 47,593[12]. - The largest shareholder, Tai'an Tang Group Co., Ltd., held 24.93% of the shares, amounting to 191,190,110 shares[12]. Operating Expenses - Total operating costs for Q1 2021 were CNY 840,912,104.35, up 7.6% from CNY 781,557,465.14 in Q1 2020[47]. - The company reported a significant increase in sales expenses, totaling CNY 122,181,455.47 in Q1 2021, compared to CNY 115,917,098.36 in Q1 2020[47]. - The company incurred an asset impairment loss of -5,085,765.31 CNY during the quarter[52]. Other Information - The company is in the process of selling up to 60% of its stake in the subsidiary Guangdong Kang Aido Digital Health Technology Co., Ltd. to focus on its main business and improve its financial structure[26]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[33]. - There were no violations regarding external guarantees during the reporting period[32]. - The company did not undergo an audit for the first quarter report[61].